bioTheranostics Receives Positive Coverage Decision and In-Network Provider Status from Tufts Health Plan for Its CancerTYPE ID® Molecular Test for Metastatic Cancer

Accurate Diagnosis is a Foundation for Personalized Medicine for Metastatic Cancer Patients

SAN DIEGO--()--bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerTYPE ID® molecular cancer classifier. Massachusetts-based Tufts Health Plan is one of the nation’s most highly rated health plans serving more than 1 million members.

CancerTYPE ID is a molecular cancer classifier that predicts tumor type in patients with metastatic cancers—among the most difficult to diagnose and treat cancers. Numerous clinical trials and economic analyses have been completed that reinforce the clinical validity and utility, prognostic performance, and cost-effectiveness of the test.

Richard Ding, president and CEO of bioTheranostics, said, “We are pleased that Tufts Health Plan is following Medicare and recognizing the value of the CancerTYPE ID test in the management of metastatic cancer. With metastatic cancer, achieving diagnostic certainty is critical to optimize site-directed therapies that reduce costs and avoid ineffective therapies for both patients and payors. This announcement is part of our efforts to work with payors across the country to make this important diagnostic test available to clinicians and cancer patients, helping to support personalized medicine with the goal of improving outcomes.”

CancerTYPE ID is becoming a standard tool in metastatic cancer management. More than 400,000 patients present with metastatic cancers in the United States each year. An accurate diagnosis of the site of origin is the first step toward personalized medicine, allowing clinicians managing these patients to treat them most effectively using site-specific therapy.

About Tufts Health Plan

Tufts Health Plan is a nonprofit organization nationally recognized for its commitment to providing innovative, high-quality healthcare coverage. The plan offers members and employers an array of health management programs, which support evidence-based approaches to health and wellness. Its HMO and POS are ranked second in the nation by the National Committee for Quality Assurance (NCQA)*. Its Tufts Medicare Preferred HMO earned a 4.5 star rating from the Centers for Medicare and Medicaid Services for 2013. Network Health, a subsidiary of Tufts Health Plan, is ranked third in the country for Medicaid plans, according to NCQA.** Headquartered in Massachusetts, Tufts Health also serves members in Rhode Island. Learn more at www.tuftshealthplan.com.

*NCQA’s Health Insurance Plan Rankings 2012-2013 — Private
**NCQA’s Health Insurance Plan Rankings 2012-2013 — Medicaid

About bioTheranostics

bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests: the CancerTYPE ID® molecular classification test; PRÉCIS® Precision Medicine, which includes biomarker profiles for non-small cell lung, colorectal, and other cancers; and Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego. Learn more at www.biotheranostics.com.

Contacts

Sullivan & Associates
Barbara Sullivan, 714-374-6174
bsullivan@sullivanpr.com

Release Summary

bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, has received a positive coverage decision and in-network provider status from Tufts Health Plan for its CancerTYPE ID®

Contacts

Sullivan & Associates
Barbara Sullivan, 714-374-6174
bsullivan@sullivanpr.com